CBUS CIBUS INC

Cibus to Participate in Upcoming August Investor Events

Cibus to Participate in Upcoming August Investor Events

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced its participation in the following August investor events.

  • Canaccord Genuity 44th Annual Growth Conference, Boston, MA – August 13-14, 2024: Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer will host a presentation beginning at 12:30 p.m. ET (9:30 a.m. PT) on August 14.

Webcast link:

  • Sidoti Micro Cap Conference, Virtual – August 14-15, 2024: Mr. Riggs and Mr. Beetham, will be meeting with investors and host a virtual presentation beginning at 3:15 p.m. ET (12:15 p.m. PT) on August 14. A live audio webcast of the presentation will be accessible through the link below:

Webcast link:

About Cibus

Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop traits to license to seed companies in exchange for royalties on seed sales. Cibus' focus is productivity traits for farmers for the major global row crops with large acreage such as canola, corn, rice, soybean, and wheat. Cibus is a technology leader in high throughput gene editing technology that enables Cibus to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. In total, Cibus has developed a pipeline of six productivity traits. It is commercializing its Pod Shatter Reduction trait in Canola and is a leader in weed management traits in Rice with its HT1 and HT3 traits with customers such as Loveland Products (Nutrien Ltd.) and Interoc S.A in the United States and Latin America. Its recent development of stacked herbicide tolerant traits in rice is an important milestone in developing better weed solutions in rice. Its other pipeline traits including Sclerotinia resistance are in advanced greenhouse and field trial stages.

CIBUS CONTACTS:

INVESTOR RELATIONS

Karen Troeber



858-450-2636

Jeff Sonnek – ICR

MEDIA RELATIONS



(619) 849-6009

Colin Sanford



203-918-4347



EN
12/08/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CIBUS INC

 PRESS RELEASE

Cibus Enters into Agreement with the Latin American Rice Hybrid Consor...

Cibus Enters into Agreement with the Latin American Rice Hybrid Consortium to Provide Cibus’ Herbicide Tolerance Trait Cibus and Centro Internacional de Agricultura Tropical (CIAT) have entered into an agreement to introduce Cibus’ proprietary herbicide tolerance trait into elite rice germplasm for Latin America Agreement represents another significant milestone as Cibus aims to bring Latin America rice growers new solutions for advanced weed management in Rice crops SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company specia...

 PRESS RELEASE

Cibus Reports Second Quarter Financial Results and Provides Year-to-Da...

Cibus Reports Second Quarter Financial Results and Provides Year-to-Date Business Update for 2025 Streamlining operational focus on Rice herbicide tolerance traits and partner-funded and/or supported programs, expected to reduce annual cash usage to approximately $30 million by 2026 Commercialization of Rice herbicide tolerance traits HT1 and HT3 on track – targeting an initial commercial launch in Latin America beginning in 2027 and expanding to the U.S. in 2028, with potential annual accessible royalties of over $200 million Signed a collaboration agreement with the Colombia based Rice ...

 PRESS RELEASE

Cibus to Report Second Quarter 2025 Financial Results on August 14, 20...

Cibus to Report Second Quarter 2025 Financial Results on August 14, 2025 After the Market Close and Host Conference Call SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report second quarter 2025 financial results on Thursday, August 14, 2025. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Q...

 PRESS RELEASE

Cibus Announces Steps to Implement More Streamlined Business Focus on ...

Cibus Announces Steps to Implement More Streamlined Business Focus on its Nearest Term Revenue Opportunities Previously Announced Strategy Focus Prioritizes Opportunities in Rice and Biofragrance Products and Sustainable Ingredients with Initiatives Expected to Reduce Annual Net Cash Usage to Approximately $30M by 2026 Cibus Well Situated to Pursue Partner Funding to Support its Advanced Productivity Trait Portfolio SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the "Company"), a leading agricultural technology company that develops plant traits to license to s...

 PRESS RELEASE

The U.S. Food and Drug Administration Completes Review of Cibus’ Alter...

The U.S. Food and Drug Administration Completes Review of Cibus’ Altered Lignin Alfalfa Developed in Partnership with S&W Seed Company for use in Livestock Feed Completion of the U.S. Food and Drug Administration’s Plant Biotechnology Consultation Program enables U.S. commercialization of alfalfa with an altered lignin profile offering potential improved digestibility for livestock and greater harvest flexibility for farmers. SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company”), a leading agricultural technology company that develops and licenses plant...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch